JOURNAL ARTICLE

Autologous bone marrow transplantation and hyperbaric oxygen therapy for patients with thromboangiitis obliterans

Shigeru Saito, Koichi Nishikawa, Hideaki Obata, Fumio Goto
Angiology 2007, 58 (4): 429-34
17652224
Many patients suffering from severe ischemic limb disease inevitably experience amputation, despite intensive therapies. Sympathectomy and hyperbaric oxygen therapy are optional therapies for patients with peripheral circulation disorders. Recently, several clinical studies have established that implantation of bone marrow-mononuclear cells into ischemic limbs increases collateral vessel formation. In the present study, autologous implantation of bone marrow-mononuclear cells was prescribed to 7 patients with ischemic limbs because of peripheral arterial disease. Although the extent of the improvement was not consistent among the 7 cases, all of the patients experienced some improvement in their symptoms. Transcutaneous oxygen partial pressure measured in a hyperbaric chamber increased in 5 patients. No side effects were observed. In conclusion, combined use of autologous bone marrow transplantation and hyperbaric oxygen therapy may be safe and effective for achievement of therapeutic angiogenesis.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
17652224
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.